MedTrace Logo

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

NCT03270579 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-04-27

No results posted yet for this study

Summary

The main purpose of the study is to measure the whole-body distribution and radiation dosimetry of \[18F\]JNJ-64511070 in healthy male participants by positron emission tomography (PET) (Part A); and to measure the uptake, binding, distribution, and washout of \[18F\]JNJ-64511070 in the brain of healthy male participants by PET and to model tissue specific kinetics of \[18F\]JNJ-64511070 with the appropriate arterial input function (IF) (Part B).

Conditions

  • Healthy

Interventions

DRUG

[18F]JNJ-64511070

An IV injection of 185 MBq \[18F\]JNJ-64511070 will be administered.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC. Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-12
Primary Completion
2018-02-06
Completion
2018-02-06

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270579 on ClinicalTrials.gov